Clinical Trial Update: HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for HM15136 (Efpegerglucagon) in treating Congenital Hyperinsulinism in subjects aged 2 years and older; study is currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Hyperinsulinism

Drugs mentioned

• Efpegerglucagon (HM15136)

Snippet

Sponsor: Hanmi Pharmaceutical Company Limited | Conditions: Congenital Hyperinsulinism | Phase 2 | Status: RECRUITING